37 episodes
Talking Precision Medicine Genialis
-
- Science
-
-
4.7 • 7 Ratings
-
Welcome to the Talking Precision Medicine podcast. In this series, we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host.
-
Cell therapy for T-cell malignancies—the science and business of developing curative medicines for patients in need | Talking Precision Medicine #37
In this episode I chat with Dr Sarah Hein, co-founder and CEO of March Biosciences, a Houston Based biotech developing cell therapies for T-cell malignancies. Sarah is an old friend and colleague from our days as trainees at Baylor College of Medicine, where we both circulated among those with ambitions of entrepreneurship. Sarah has definitely made good in that regard, as a serial entrepreneur deeply enmeshed in Houston’s growing life sciences and healthtech ecosystem.
Episode 37 links:
TPM E37 for highlights and links from this episode >
Genialis’ Upcoming Events
Genialis™ krasID -
Tackling healthcare disparities and bridging the digital divide: it doesn’t have to be so hard | Talking Precision Medicine #36
This episode features two guests, Jennifer Goldsack and Yashoda Sharma, of the Digital Medicine Society, or DiMe. We’re going to get into the nitty gritty of healthcare disparities in terms of access and outcomes, and how digital solutions are a big part of the overall solution.
Episode 36 links:
TPM E36 for highlights and links from this episode >
Genialis’ Upcoming Events
Genialis™ krasID -
The Science and Art of De-risking Cancer Drug Development | Talking Precision Medicine #35
In this episode Genialis CEO Rafael Rosengarten sat down with Dr. Carolina Haefliger, head of translational medicine at Debiopharm, the privately held Swiss biopharma company focused on oncology drug development. They talked about de-risking promising new cancer drugs, and what it takes from the science to the team to the technologies.
Episode 35 links:
Visit TPM E35 for highlights and links from this episode >
Learn more about Genialis™ krasID >
New Genialis RNA Biomarker Accurately Predicts KRAS Outcomes in Lung Cancer Patients > -
Professional grade software — a key ingredient in cutting edge biomedical discovery | Talking Precision Medicine #34
Today we turn the mic around, as our guest Adam Stasio hosts an excellent podcast of his own. Adam’s day job, however, is running SciMed, a boutique life sciences software development company. Adam and Genialis CEO Rafael Rosengarten discuss the state of scientific software, the importance of agility and communication, and approaches to building a lasting company culture.
Visit TPM E34 for highlights and links from this episode. -
New Medicines from Evolutionary Pathways: Using Comparative Genomics to Treat Human Disease | Talking Precision Medicine #33
Our guest today is Dr. Ashley Zehnder, co-founder and CEO of Fauna Bio. Fauna is a revolutionary young biotech company using comparative genomics of an array of non-traditional mammalian models to discover new therapeutic opportunities for people. What do ground squirrels have to do with treating battlefield trauma? Only one way to find out …
Visit TPM E33 for highlights and links from this episode. -
To achieve personalized medicine, start by getting the dose right | Talking Precision Medicine #32
In this episode, Genialis CEO Rafael Rosengarten sits down with Ajay Gopal, CEO and founder of Rx Studio. Rx Studio is a technology company using data science to tackle a major limitation to personalized medicine: drug dosing.
Visit TPM E32 for highlights and links from this episode.
Customer Reviews
Great conversations
Absolutely my favorite podcast to host!
Interesting topics
Informative podcast by a great mind bringing on innovative guests.
Interview with Leaders in the field
Great take on precision medicine including bioinformatics, big data, cell therapy, and gene therapy.